There are several compounds interfering with the Wnt/β-Catenin pathway tested in preclinical studies for treatment of CKD summarized in41, for example the Wnt/β-Catenin blocker geraniol42, prorenin receptor antagonist PRO-2043 or pachymic acid that upregulates Wnt signaling44. The gene discussed is ATP6AP2; the disease is chronic kidney disease.